Impact of HAART on liver histology of HIV/HCV coinfected patients.
The impact of HAART on the progression of HCV related liver disease is controversial. This retrospective study compares the grading and staging of chronic viral hepatitis in HIV/HCV coinfected subjects treated or not with antiretroviral therapy (ART) including protease inibithors (PI). The liver histology of 44 HIV/HCV coinfected patients on ART for more than 12 months, 26 coinfected patients naïve for ART and 31 HCV monoinfected patients were analysed by the Ishak score. None of the multivariate models calculated to test if liver histopathology (Ishak grading or staging) between HIV/HCV coinfected patients versus HCV monoinfected or antiretroviral-treated versus untreated HIV+ subjects showed any statistical difference. No significant difference between grading and staging was evidenced either in PI treated subjects versus patients on ART without PI.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001706:Biopsy; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D005355:Fibrosis; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007249:Inflammation / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology*; D011480:Protease Inhibitors / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood / Q000235:genetics
D011480:Protease Inhibitors; D012367:RNA, Viral; D000410:Alanine Transaminase